Tags : Expand


Boehringer Ingelheim and MD Anderson Expand their Collaboration to Accelerate

Shots: Boehringer Ingelheim and MD Anderson expand their 2019 joint VRDC to explore new molecules from Boehringer Ingelheim’s KRAS and TRAILR2 portfolios for lung cancer, particularly NSCLC The joint research will continue for 5 additional years. The extended collaboration follows successful preclinical studies in GI cancers via joint VRDC The expanded agreement allows the partners […]Read More


Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology

Shots: Novartis gets an exclusive WW right to develop and commercialize therapeutic applications for FAP assets including FAPI-46 and FAPI-74 under its collaboration with iTheranostics, which is an affiliate of SOFIE Biosciences The agreement also consists of co-exclusive rights for Novartis to develop imaging applications for FAP assets The company will continue to reimagine cancer […]Read More


Samsung Bioepis Expand its Footprints with the Launch of Hadlima

Shots: Samsung Bioepis in collaboration with Merck broadens its global reach by launching Hadlima in Australia for multiple autoimmune diseases With the launch in Australia, Samsung Bioepis’ adalimumab is now available in three markets: Europe, Canada, and Australia Hadlima is Samsung Bioepis’ third anti-TNF biosimilar launched in Australia, following the launch of Brenzys (etanercept) and […]Read More

M&A MedTech

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

Shots: Immunai acquires the Dropprint Genomics and also expand its team with the hiring of new experts in immunology, single-cell technologies and machine learning The acquisition and the new hiring will advance the Immunai’s work in single cell functional genomics to support discovery, prioritization, and development of new therapies and drug combinations The acquisition happened […]Read More


mAbxience Collaborates with ABEC to Expand Biosimilar and CDMO Manufacturing

Shots: mAbxience will equip their state-of-the-art cGMP facility in Spain with an ABEC 4,000L CSR Bioreactor The system will be commissioned mid-2021 and will increase biosimilar and CDMO manufacturing capacity at the León site The 4,000L volume & performance comparable to stainless steel systems will enable mAbxience to improve flexibility, productivity and efficiency. The CSR […]Read More

M&A MedTech

Haemonetics to Acquire Cardiva Medical for ~$510M

Shots: Cardiva to receive $475M up front and up to an additional ~$35M in contingent consideration based on sales growth. The transaction is expected to be completed in Q1’21 The acquisition expands Haemonetics’ blood transfusion and loss management offerings and enhance its penetration into the large and growing interventional cardiology and electrophysiology markets Cardiva’s portfolio […]Read More


Pfizer And LianBio Collaborate to Expand the Development of Novel

Shots: Pfizer & LianBio collaborate to focus at developing & commercializing transformative therapies in Greater China. Both the companies will leverage their clinical development, regulatory and commercial expertise Pfizer will contribute ~$70M of non-dilutive capital toward in-licensing & co-development. At LianBio’s discretion, products will be presented to Pfizer for joint development Pfizer will have a […]Read More


J&J and US Government Amends their Agreement for the Next

Shots: J&J and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development Janssen will commit ~$604M while BARDA will commit ~$454M to support the ongoing P-lll ENSEMBLE study assessing Janssen’s JNJ-78436735 as a single-dose in ~60,000 patients globally J&J affirmed […]Read More


Alvotech and Cipla Collaborate to Ensure Access to Biosimilars in

Shots: Alvotech and Cipla entered an exclusive partnership to provide patients with better access to high quality and cost-effective biosimilar medicines in South Africa Alvotech will be responsible for the development and supply of the products and Cipla will be responsible for the registration and commercialization The biosimilar portfolio will include five biosimilars- two for […]Read More